December 22, 2015 Off

Janssen and Bavarian Nordic to develop vaccine for Chronic Human Papillomavirus (HPV) infections

By Dino Mustafić

Janssen Pharmaceuticals, Inc. (Janssen) has entered into a definitive collaboration and license agreement with Bavarian Nordic to leverage their MVA-BN technology, jointly with Janssen’s own AdVac technology, in the development and commercialization of a heterologous prime-boost vaccine for the treatment of Human Papillomavirus (HPV) chronic infections which can lead to cancer.